Daniel is a Director of the MedTech practice at Broadview Ventures, a mission-driven early-stage investor focused on improving human health in the areas of cardiovascular disease and stroke. Prior to Broadview, he held a variety of roles in marketing, strategy, corporate venture capital, and business development at Guidant, Abbott Vascular, and Proteon Therapeutics. Daniel currently holds board positions at Alleviant, XII Medical, Cardiosense, CroíValve, Nyra Medical and CorFlow. Daniel holds a BA from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth.